Literature DB >> 27388010

Comprehensive Identification and Quantitation of Basic Building Blocks for Low-Molecular Weight Heparin.

Xiaojun Sun1,2, Anran Sheng1, Xinyue Liu1,2, Feng Shi3, Lan Jin1, Shaoshuai Xie1, Fuming Zhang2, Robert J Linhardt2, Lianli Chi1.   

Abstract

Low-molecular weight heparins (LMWHs) are widely used anticoagulant drugs. They inherit the heterogeneous backbone sequences of the parent heparin, while the chemical depolymerization process modifies the nonreducing end (NRE) and reducing end (RE) of their sugar chains. Some side reactions may also occur and increase the structural complexity of LMWHs. It is important to precisely characterize the structures of LMWHs, especially their chemical modifications, to ensure drug quality and safety. Compositional analysis provides a powerful approach to reveal the building blocks that make up the LMWHs, which are the mutual consequence of the heparin starting materials and the manufacturing process. Here, we introduce a comprehensive analytical method to recover the most basic building blocks of LMWHs. A strategy of combining both enzymatic digestion and oxidative degradation of LMWH was used to make the NRE, RE, and backbone structures differentiable from one another. Satisfactory separation, identification, and quantitation were achieved by coupling hydrophilic interaction chromatography with a triple quadrupole mass spectrometer operating under the multiple reaction monitoring mode. After enzymatic digestion, over 30 species were detected, with both natural and chemically modified heparin basic building blocks. Two novel structures, including a trisaccharide containing two glucosamine residues and a tetrasaccharide containing a 3-O-sulfated uronic acid residue, were discovered. Reduced and oxidatively degraded samples were analyzed to provide the complementary information on both termini of LMWHs. The reproducibility of this method was evaluated, and enoxaparin injections were analyzed to demonstrate the application of this method for evaluating the sameness of LMWH products.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27388010     DOI: 10.1021/acs.analchem.6b01709

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

Review 1.  Recent advances in biotechnology for heparin and heparan sulfate analysis.

Authors:  Meng Qiao; Lei Lin; Ke Xia; Jun Li; Xing Zhang; Robert J Linhardt
Journal:  Talanta       Date:  2020-06-14       Impact factor: 6.057

2.  Heparin/heparan sulfate analysis by covalently modified reverse polarity capillary zone electrophoresis-mass spectrometry.

Authors:  Patience Sanderson; Morgan Stickney; Franklin E Leach; Qiangwei Xia; Yanlei Yu; Fuming Zhang; Robert J Linhardt; I Jonathan Amster
Journal:  J Chromatogr A       Date:  2018-02-24       Impact factor: 4.759

3.  Specific Non-Reducing Ends in Heparins from Different Animal Origins: Building Blocks Analysis Using Reductive Amination Tagging by Sulfanilic Acid.

Authors:  Pierre A J Mourier
Journal:  Molecules       Date:  2020-11-26       Impact factor: 4.411

4.  Commercial Low Molecular Weight Heparins - Patent Ecosystem and Technology Paradigm for Quality Characterization.

Authors:  Zarina Iqbal; Saima Sadaf
Journal:  J Pharm Innov       Date:  2022-07-28       Impact factor: 2.538

Review 5.  Analysis of the Glycosaminoglycan Chains of Proteoglycans.

Authors:  Yuefan Song; Fuming Zhang; Robert J Linhardt
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 6.  Investigation of the biological functions of heparan sulfate using a chemoenzymatic synthetic approach.

Authors:  Zhangjie Wang; Katelyn Arnold; Vijay Manohar Dhurandhare; Yongmei Xu; Jian Liu
Journal:  RSC Chem Biol       Date:  2021-02-22

Review 7.  Developments in Mass Spectrometry for Glycosaminoglycan Analysis: A Review.

Authors:  Lauren E Pepi; Patience Sanderson; Morgan Stickney; I Jonathan Amster
Journal:  Mol Cell Proteomics       Date:  2021-01-06       Impact factor: 5.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.